Biotech · Private company
Thryv Therapeutics, Inc.
Track this companyFree. Adds Thryv Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- baseline lead-inPhase 3 · Long QT Syndrome (LQTS) 2ClinicalTrials.gov · fetched Nov 12, 2026
- THRV-1268Phase 3 · Long QT Syndrome (LQTS) 2ClinicalTrials.gov · fetched Nov 12, 2026
- Dofetilide 250 μg CapPhase 2 · Long QT SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- LQT-1213Phase 2 · Long QT SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- THRV-1268Phase 1 · Heart FailureClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)PHASE2_PHASE3 · RECRUITING · started Mar 7, 2026ClinicalTrials.gov NCT07277582 · fetched Nov 12, 2026
- Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3ACTIVE_NOT_RECRUITING · started Oct 27, 2025ClinicalTrials.gov NCT07075445 · fetched Nov 12, 2026
- Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult ParticipantsPHASE1 · COMPLETED · started Sep 15, 2025ClinicalTrials.gov NCT07186946 · fetched Nov 12, 2026
- Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).PHASE1_PHASE2 · TERMINATED · started Mar 12, 2023ClinicalTrials.gov NCT05906732 · fetched Nov 12, 2026
- Phase 1 Study of LQT-1213 in Healthy AdultsPHASE1 · COMPLETED · started Sep 14, 2022ClinicalTrials.gov NCT05759962 · fetched Nov 12, 2026